Puma Biotechnology (Puma Biotechnology) Total Liabilities : $177.1 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology Total Liabilities?

Puma Biotechnology's Total Liabilities for the quarter that ended in Dec. 2023 was $177.1 Mil.

Puma Biotechnology's quarterly Total Liabilities declined from Jun. 2023 ($170.10 Mil) to Sep. 2023 ($164.86 Mil) but then increased from Sep. 2023 ($164.86 Mil) to Dec. 2023 ($177.09 Mil).

Puma Biotechnology's annual Total Liabilities declined from Dec. 2021 ($229.03 Mil) to Dec. 2022 ($200.45 Mil) and declined from Dec. 2022 ($200.45 Mil) to Dec. 2023 ($177.09 Mil).

Puma Biotechnology Total Liabilities Historical Data

The historical data trend for Puma Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology Total Liabilities Chart

Puma Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

217.44

250.17

229.03

200.45

177.09

Puma Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															200.45	170.41	170.10	164.86	177.09

Puma Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Puma Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	99.382	+	(72.693	+	5.011
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	177.1

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	230.528	-	53.442
	=	177.1

Puma Biotechnology's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	99.382	+	(72.693	+	5.011
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	177.1

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	230.528	-	53.442
	=	177.1

Puma Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Puma Biotechnology (Puma Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024

Website

http://www.pumabiotechnology.com

Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.

Executives

Alan H Auerbach	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong	officer: Chief Scientific Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues	officer: Chief Financial Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig	officer: Chief Commercial Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt	officer: See Remarks	C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz	director	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval	director	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik	director	C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes	director
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce	officer: SR VP, CLINICAL RESEARCH & DEV	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd	director	C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139